The good and bad effects of statins on insulin sensitivity and secretion

Endocrine Research

Volumn 39, Issue 4, 2014, Pages 137-143

  Muscogiuri, Giovanna ^a   Sarno, Gerardo ^b   Gastaldelli, Amalia ^c   Savastano, Silvia ^a   Ascione, Antonio ^d   Colao, Annamaria ^a   Orio, Francesco ^b,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Cardiovascular disease; Dyslipidemia; Insulin resistance; Insulin secretion; Statins; Type 2 diabetes

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; ATORVASTATIN; CERIVASTATIN; COMPACTIN; EZETIMIBE PLUS SIMVASTATIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VOLTAGE GATED CALCIUM CHANNEL;

ADIPOCYTE; CLINICAL STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DYSLIPIDEMIA; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; ANIMAL; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; ENZYMOLOGY; EVIDENCE BASED MEDICINE; LIVER; METABOLISM; PATIENT EDUCATION; RISK; RISK ASSESSMENT; SECRETION (PROCESS);

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; PATIENT EDUCATION AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK ASSESSMENT;

EID: 84911474003     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2014.952018     Document Type: Review

References (63)

1. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
2. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
3. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
4. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19: 117-25.
5. Hu M, Tomlinson B. Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics. 2013;14:981-95.
6. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011;65: 1141-8.
7. Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009;63:1308-13.
8. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75.
9. Gannagé-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005;54:947-51.
10. Meex RC, Phielix E, Schrauwen-Hinderling VB, et al. The use of statins potentiates the insulin-sensitizing effect of exercise training in obese males with and without Type 2 diabetes. Clin Sci (Lond) 2010;119:293-301.
11. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in non-diabetic dyslipidemic patients. Endocrine 2003; 22:151-4.
12. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
13. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87: 98-107.
14. Gaw A, Packard CJ. Comparative chemistry, pharmacology and mechanism of action of the statin. In: Gaw A, Packard CJ, Sheperd J (Eds) Statins. The HMG CoA reductase inhibitors in perspective. Martin Dunitz, London; 2000:49-61.
15. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4-12.
16. Liao JK. Role of statin pleiotropism in acute coronary syndromes and stroke. Int J Clin Pract Suppl 2003;134:51-7.
17. Wu T, Fujihara M, Tian J, et al. Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels. J Neurochem 2010;114:1734-44.
18. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. Heart Vessels 2010; 25:288-93.
19. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
20. Wagner AH, Köhler T, Rückschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9.
21. Yin H, Shi ZG, Yu YS, et al. Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats. Eur J Pharmacol 2012;674:200-6.
22. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002; 164:179-85.
23. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001;5:378-87.
24. Bellosta S, Arnaboldi L, Gerosa L, et al. Statins effect on smooth muscle cell proliferation. Semin Vasc Med 2004;4:347-56.
25. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004;35:2708-11.
26. Cicha I, Schneiderhan-Marra N, Yilmaz A, et al. Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo. Arterioscler Thromb Vasc Biol 2004;24:2046-50.
27. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442-9.
28. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
29. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
30. Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
31. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357: 2248-61.
32. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
33. Holman RR, Paul S, Farmer A, et al; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009;52:50-9.
34. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
35. Axsom K, Berger JS, Schwartzbard AZ. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep. 2013 Feb;15(2):2.doi:10.1007/s11883-012-0299-z
36. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
37. Gannagé-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy non-diabetic patients. Metabolism 2005;54:947-51.
38. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in non obese type 2 diabetic patients. Diabetes Care 2009;32:209-14.
39. Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010;210:199-201.
40. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011;65: 1141-8.
41. Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009;63:1308-13.
42. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150:121-7.
43. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-51.
44. Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21.
45. Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184:348-55.
46. Lalli CA, Pauli JR, Prada PO, et al. Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metabolism 2008;57:57-65.
47. Guo H, Lv H, Tang W, et al. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterollowering effect in insulin-resistant mice. Cardiovasc Drugs Ther. 2012;26:375-82.
48. Le Lay S, Krief S, Farnier C, et al. Cholesterol, a cell sizedependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem 2001;276:16904-10.
49. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507: 357-61.
50. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49:1881-92.
51. Mita T, Nakayama S, Abe H, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig 2013;4:297-303.
52. Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012;223:197-203.
53. Paniagua JA, López-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002;51:2596-603.
54. Martin S, Herder C, Schloot NC, et al; DIATOR Study Group. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 2011;11;6:e17554.
55. Strom A, Kolb H, Martin S, et al; DIATOR Study Group. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012;7:e33108.
56. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13.
57. Tsuchiya M, Hosaka M, Moriguchi T, et al. Cholesterol biosynthesis pathway intermediates and inhibitors regulate glucosestimulated insulin secretion and secretory granule formation in pancreatic beta-cells. Endocrinology 2010;151:4705-16.
58. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006;13: 329-35.
59. Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008;149:5136-45.
60. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. US Food and Drug Administration; 2012.
61. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45.
62. Axsom K, Berger JS, Schwartzbard AZ. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep 2013;15: 299.
63. Sattar N, Taskinen MR. Statins are diabetogenic-myth or reality? Atheroscler Suppl 2012;13:1-10.